Trial Profile

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2023 Results of an analysis assessing matching-adjusted indirect comparison (MAIC) of Pirtobrutinib vs Venetoclax continuous monotherapy from two clinical trials: NCT03740529 and NCT02141282 presented at the 28th Congress of the European Haematology Association
29 Dec 2021 Status changed from active, no longer recruiting to completed.
08 Dec 2020 Results (n=1138) of a retrospective analysis assessing rates of tumor lysis syndrome and outcomes and data were pooled from eight clinical studies: M15-550, M15-889, CLL14, M16-778, M14-032, M13-982, M14-728 and MURANO presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com